Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Lyra Therapeutics (LYRA) Research & Development (2021 - 2025)

Lyra Therapeutics has reported Research & Development over the past 5 years, most recently at $4.4 million for Q4 2025.

  • Quarterly results put Research & Development at $4.4 million for Q4 2025, down 31.19% from a year ago — trailing twelve months through Dec 2025 was $18.4 million (down 57.93% YoY), and the annual figure for FY2025 was $18.4 million, down 57.93%.
  • Research & Development for Q4 2025 was $4.4 million at Lyra Therapeutics, up from $4.0 million in the prior quarter.
  • Over the last five years, Research & Development for LYRA hit a ceiling of $18.2 million in Q1 2024 and a floor of $4.0 million in Q3 2025.
  • Median Research & Development over the past 5 years was $9.0 million (2022), compared with a mean of $8.9 million.
  • Biggest five-year swings in Research & Development: surged 78.3% in 2022 and later plummeted 73.26% in 2025.
  • Lyra Therapeutics' Research & Development stood at $10.3 million in 2021, then dropped by 8.62% to $9.5 million in 2022, then increased by 29.79% to $12.3 million in 2023, then crashed by 48.13% to $6.4 million in 2024, then tumbled by 31.19% to $4.4 million in 2025.
  • The last three reported values for Research & Development were $4.4 million (Q4 2025), $4.0 million (Q3 2025), and $5.1 million (Q2 2025) per Business Quant data.